Damon Race/LinkedIn
Jun 25, 2026, 15:28
Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared a post on LinkedIn:
“Met up with my friends from ReciPharm Advanced Bio at BIO International 2026.
ReciPharm is a wonderful partner in our efforts to advance GENV-HEM, the first gene therapy with durable expression biology for patients with hemophilia A with or without inhibitors.
A special thank you to Greg Behar and Jhomar Marquez.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering